VenatoRx Pharmaceuticals
Latest round
- Series C
Last raised
- Aug 2022
Total raised
- $92M
Investors
- 5
About VenatoRx Pharmaceuticals
VenatoRx Pharmaceuticals, Inc.Founded in 2010 and headquartered in Malvern, US, VenatoRx Pharmaceuticals specializes in anti-infective drug development.000 mn.Venatorx Pharmaceuticals specializes in the discovery and development of innovative anti-infectives targeting multi-drug-resistant (MDR) bacterial infections and challenging viral infections. The company's core offerings include advanced drug candidates such as Cefepime-Taniborbactam and Ceftibuten-Ledaborbactam, which are designed to combat specific pathogens that have become resistant to conventional treatments. These products aim to address significant medical needs in healthcare settings, particularly in hospitals where patients are at high risk for MDR infections. Venatorx's solutions are primarily directed toward healthcare providers, including hospitals and specialty clinics, as well as pharmaceutical partners engaged in the commercialization of these critical therapies.Venatorx Pharmaceuticals generates revenue through strategic partnerships and collaborations with other pharmaceutical entities, particularly in the commercialization of its drug candidates. The company engages in B2B transactions with healthcare institutions and pharmaceutical companies, where its flagship products are supplied under negotiated terms that may involve milestone payments and royalties based on sales performance. Venatorx’s revenue structure is closely tied to the successful development and approval of its products, which can lead to lucrative agreements with partners looking to enhance their portfolios in the anti-infective space. The company plans to leverage this capital to advance the development of new products targeting MDR infections and explore geographic expansion into additional markets in Europe and North America. The firm is focused on enhancing its product pipeline to meet the urgent medical needs posed by resistant pathogens.
Who invested in VenatoRx Pharmaceuticals
5 investors across 4 rounds
See all investors in VenatoRx Pharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about VenatoRx Pharmaceuticals
Who invested in VenatoRx Pharmaceuticals?
VenatoRx Pharmaceuticals has 5 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has VenatoRx Pharmaceuticals raised?
VenatoRx Pharmaceuticals has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did VenatoRx Pharmaceuticals last raise money?
VenatoRx Pharmaceuticals's most recent round on record is a Series C, in Aug 2022.
What does VenatoRx Pharmaceuticals do?
VenatoRx Pharmaceuticals is a pharmaceuticals company.
Where is VenatoRx Pharmaceuticals headquartered?
VenatoRx Pharmaceuticals is headquartered in Malvern, US.
Which VCs invest in companies like VenatoRx Pharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back pharmaceuticals companies at VenatoRx Pharmaceuticals's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like VenatoRx Pharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.